What Actemra treats
Actemra (tocilizumab) is a biologic medication specifically designed to treat chronic inflammatory conditions such as moderate to severe rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (sJIA), and giant cell arteritis (GCA). By targeting and inhibiting the interleukin-6 (IL-6) receptor, Actemra helps reduce inflammation and alleviate symptoms.
Benefits of Actemra
The treatment goals in the conditions Actemra is approved to treat include reduced joint pain, improved mobility, and better management of systemic inflammation. Whether an individual patient reaches them varies, and is assessed by the prescribing clinician. Its dual administration routes—intravenous infusion and subcutaneous injection—offer flexibility and convenience in treatment.
Possible Side Effects of Actemra
Some patients experience side effects, including upper respiratory infections, headaches, and increased blood pressure. Injection site reactions like redness or swelling are also possible with the subcutaneous form. Serious side effects can include an increased risk of infections, liver enzyme abnormalities, and gastrointestinal perforations. It’s essential to monitor your health and report any unusual symptoms to your healthcare provider.
How infusion works at Prime
Actemra is administered at our infusion centers across New York and Atlanta. Our dedicated care team coordinates every step of your treatment with your prescribing physician.
Getting started
Patients: if you have a referral for Actemra, send us an inquiry using the form below and our care team will take it from there. Physicians: referring a patient to Prime Infusions is simple — just complete and fax or email the referral form above.
Ready to start?
For a medical emergency, call 911.
Our Infusion Centers
FAQ
Frequently asked questions
How Does Actemra Work?
Actemra works by blocking the IL-6 receptor, a protein involved in the inflammatory process. By interfering with IL-6 signaling, Actemra reduces inflammation, leading to improved joint function in RA, better control of symptoms in sJIA, and reduced inflammation in GCA. Actemra is administered through intravenous infusion or subcutaneous injection, with dosing tailored to the patient’s specific condition.
Who is Actemra For?
Actemra is ideal for adults with moderate to severe RA who have not responded adequately to other treatments. It is also prescribed for children aged 2 years and older with sJIA, as well as adults with GCA. Actemra is often recommended when previous therapies have been ineffective or unsuitable.